EP0991759A1 - Ntn-2, mitglied von tnf-ligand-familie - Google Patents
Ntn-2, mitglied von tnf-ligand-familieInfo
- Publication number
- EP0991759A1 EP0991759A1 EP98923907A EP98923907A EP0991759A1 EP 0991759 A1 EP0991759 A1 EP 0991759A1 EP 98923907 A EP98923907 A EP 98923907A EP 98923907 A EP98923907 A EP 98923907A EP 0991759 A1 EP0991759 A1 EP 0991759A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- human ntn
- human
- ntn
- polypeptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Definitions
- the field of this invention is polypeptide molecules which regulate cell function, nucleic acid sequences encoding the polypeptides, and methods of using the nucleic acid sequences and the polypeptides.
- Tumor necrosis factor-alpha is a cytokine primarily produced by activated macrophages. TNF-alpha stimulates T-cell and B-cell proliferation and induces expression of adhesion molecules on endothelial cells. This cytokine also plays an important role in host defense to infection.
- TNF-alpha activities are mediated through two distinct receptors, TNFR-p55 and TNFR-p75. These two receptors also mediate activities triggered by soluble lymphotoxin-alpha (LT-alpha) secreted mainly by activated lymphocytes.
- LT-alpha soluble lymphotoxin-alpha
- Specific stimulation of TNFR-p55 induces TNF activities such as in vitro tumor cell cytotoxicity, expression of adhesion molecules on endothelial cells and keratinocytes, activation of sphingomyelinase with concomitant increases of ceramide, activation of NF-kappaB and induction of manganese superoxide dismutase mRNA.
- Specific stimulation of TNFR- p75 results in proliferative response of mouse and human thymocytes and cytoxic T cells, fibroblasts and natural killer cells and in GM-CSF secretion in PC60 cells.
- TNF especially in combination with gamma. -interferon (IFN-. gamma.)
- IFN-. gamma. has the ability to selectively kill or inhibit malignant cell lines that is unmatched by any other combination of cytokines.
- Clinical trials in cancer patients with TNF-. alpha, antitumor therapy have been disappointing, however, because the toxic side effects of TNF have prevented obtaining effective dose levels in man.
- These toxic side effects have been attributed to TNF binding to the TNFR-p75 receptor while the cytotoxic activity on malignant cells has been attributed to binding of TNF to the TNFR-p55 receptor.
- the subject invention is a molecule that is homologous to tumor necrosis factor (TNF).
- TNF tumor necrosis factor
- the invention provides methods and compositions relating to the molecule, HUMAN NTN-2 polypeptide, and related nucleic acids. Included are polypeptides comprising a HUMAN NTN-2-specific domain and having HUMAN NTN-2 -specific activity. The polypeptides may be produced recombinantly from transformed host cells with the subject nucleic acids.
- the invention provides binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g., genetic hybridization screens for HUMAN NTN-2 transcripts), therapy (e.g., gene therapy to modulate HUMAN NTN-2 gene expression) and in the biopharmaceutical industry (e.g., reagents for screening chemical libraries for lead pharmacological agents).
- diagnosis e.g., genetic hybridization screens for HUMAN NTN-2 transcripts
- therapy e.g., gene therapy to modulate HUMAN NTN-2 gene expression
- biopharmaceutical industry e.g., reagents for screening chemical libraries for lead pharmacological agents.
- Preferred uses for the subject HUMAN NTN-2 polypeptides include modifying the physiology of a cell comprising an extracellular surface by contacting the cell or medium surrounding the cell with an exogenous HUMAN NTN-2 polypeptide under conditions whereby the added polypeptide specifically interacts with a component of the medium and/or the extracellular surface to
- Also preferred are methods for screening for biologically active agents which methods involve incubating a HUMAN NTN-2 polypeptide in the presence of an extracellular HUMAN NTN-2 polypeptide-specific binding target and a candidate agent, under conditions whereby, but for the presence of the agent, the polypeptide specifically binds the binding target at a reference affinity; detecting the binding affinity of the polypeptide to the binding target to determine an agent-biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that the agent modulates the binding of the polypeptide to the binding target.
- HUMAN NTN-2 Based upon its homology to TNF, it is expected that HUMAN NTN-2 will be a mediator of immune regulation and inflammatory response, closely linked to the development of disease. It may be useful for regulating development, proliferation and death of cells of the lymphoid, hematopoitic and other lineages. Also, HUMAN NTN-2 may be of use in the prevention of septic shock, autoimmune disorders and graft-host disease. Furthermore, HUMAN NTN-2 polypeptide may be used to identify its receptor.
- FIGURE 1 Northern analysis of various human tissue specific RNAs using a 608 nucleotide fragment of the HUMAN NTN-2 sequence as a probe. Lanes 1 - 8 in order as follows: Heart, Brain, Placenta, Lung, Liver, Skeletal Muscle, Kidney and Pancreas. DETAILED DESCRIPTION OF THE INVENTION
- the invention provides HUMAN NTN-2 polypeptide which includes natural HUMAN NTN-2 polypeptide and recombinant polypeptides comprising a HUMAN NTN-2 amino acid sequence, or a functional
- HUMAN NTN-2 polypeptide domain thereof having an assay-discernable HUMAN NTN-2-specific activity. Accordingly, the polypeptides may be deletion mutants of the disclosed natural HUMAN NTN-2 polypeptides and may be provided as fusion products, e.g., with non- HUMAN NTN-2 polypeptides.
- the subject HUMAN NTN-2 polypeptide domains have
- HUMAN NTN-2 A number of applications for HUMAN NTN-2 are suggested from its properties. HUMAN NTN-2, may be useful in the study and treatment of conditions similar to those which are treated using TNF. Furthermore, the
- HUMAN NTN-2 cDNA may be useful as a diagnostic tool, such as through use of antibodies in assays for polypeptides in cell lines or use of oligonucleotides as primers in a PCR test to amplify those with sequence similarities to the oligonucleotide primer, and to see how much HUMAN NTN-2 is present.
- the isolation of HUMAN NTN-2 also provides the key to isolate its putative receptor, other HUMAN NTN-2 binding polypeptides, and/or study its antagonistic properties.
- HUMAN NTN-2-specific activity or function may be determined by convenient in vitro, cellbased, or in vivo assays - e.g., in vitro binding assays, cell culture assays, in animals (e.g., immune response, gene therapy, transgenics, etc.), etc. Binding assays encompass any assay where the specific molecular interaction of a HUMAN NTN-2 polypeptide with a binding target is evaluated.
- the binding target may be a natural binding target, or a non-natural binding target such as a specific immune polypeptide such as an antibody, or a HUMAN NTN-2 specific agent such as those identified in assays described below.
- the claimed polypeptides may be isolated or pure - an "isolated" polypeptide is one that is no longer accompanied by some of the material with which it is associated in its natural state, and that preferably constitutes at least about 0.5%, and more preferably at least about 5% by weight of the total polypeptide in a given sample; a "pure" polypeptide constitutes at least about 90%, and preferably at least about 99% by weight of the total polypeptide in a given sample.
- the subject polypeptides and polypeptide domains may be synthesized, produced by recombinant technology, or purified from cells.
- the subject polypeptides find a wide variety of uses including use as immunogens, targets in screening assays, bioactive reagents for modulating cell growth, differentiation and /or function, etc.
- the invention provides methods for modifying the physiology of a cell comprising an extracellular surface by contacting the cell or medium surrounding the cell with an exogenous HUMAN NTN-2 polypeptide under conditions whereby the added polypeptide specifically interacts with a component of the medium and /or the extracellular surface to effect a change in the physiology of the cell.
- the extracellular surface includes plasma membrane-associated receptors;
- the exogenous HUMAN NTN-2 refers to a polypeptide not made by the cell or, if so, expressed at non-natural levels, times or physiologic locales; and suitable media include in vitro culture media and physiological fluids such as blood, synovial fluid, etc.
- the polypeptides may be may be introduced, expressed, or repressed in specific populations of cells by any convenient way such as microinjection, promoter-specific expression of recombinant enzyme, targeted delivery of lipid vesicles, etc.
- the invention provides natural and non-natural HUMAN NTN-2-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development.
- HUMAN NTN-2-specific binding agents include HUMAN NTN-2-specific receptors, such as somatically recombined protein receptors like specific antibodies or
- T-cell antigen receptors See, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory) and also includes other natural binding agents identified with assays such as one-, two- and three- hybrid screens, and non-natural binding agents identified in screens of chemical libraries such as described below. Agents of particular interest modulate HUMAN NTN-2 function.
- the invention provides HUMAN NTN-2 nucleic acids, which find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc., as well as use in detecting the presence of HUMAN NTN-2 genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional HUMAN NTN-2 homologs and structural analogs.
- the subject nucleic acids are of synthetic /non-natural sequences and /or are isolated, i.e., no longer accompanied by some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of total nucleic acid present in a given fraction, and usually recombinant, meaning they comprise a non- natural sequence or a natural sequence joined to nucleotide(s) other than that which it is joined to on a natural chromosome.
- Nucleic acids comprising the nucleotide sequence disclosed herein and fragments thereof contain such sequence or fragment at a terminus, immediately flanked by a sequence other than that to which it is joined on a natural chromosome, or flanked by a native flanking region fewer than 10 kb, preferably fewer than 2 kb, which is immediately flanked by a sequence other than that to which it is joined on a natural chromosome. While the nucleic acids are usually RNA or DNA, it is often advantageous to use nucleic acids comprising other bases or nucleotide analogs to provide modified stability, etc.
- the amino acid sequences of the disclosed HUMAN NTN-2 polypeptide is used to back translate HUMAN NTN-2 polypeptide-encoding nucleic acids optimized for selected expression systems (Holler, et al. (1993) Gene 136: 323- 328; Martin, et al. (1995) Gene 154: 150-166) or used to generate degenerate oligonucleotide primers and probes for use in the isolation of natural HUMAN NTN-2 encoding nucleic acid sequences ("GCG” software, Genetics Computer Group, Inc., Madison, WI).
- HUMAN NTN-2 encoding nucleic acids may be part of expression vectors and may be incorporated into recombinant host cells, e.g., for expression and screening, for transgenic animals, for functional studies such as the efficacy of candidate drugs for disease associated with HUMAN NTN-2 mediated signal transduction, etc.
- Expression systems are selected and /or tailored to effect HUMAN NTN-2 polypeptide structural and functional variants through alternative post- translational processing.
- the invention also provides for nucleic acid hybridization probes and replication /amplification primers having a HUMAN NTN-2 cDNA specific sequence and sufficient to effect specific hybridization with SEQ. I.D. NO. 1.
- Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5 x SSPE (0.18 M NaCl, 0.01 M NaP0 4 , pH7.7, 0.001 M EDTA) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2x SSPE buffer at 42°C.
- HUMAN NTN-2 cDNA homologs can also be distinguished from other polypeptides using alignment algorithms, such as BLASTX (Altschul, et al. (1990) Basic
- HUMAN NTN-2 hybridization probes find use in identifying wild-type and mutant alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific oligonucleotide (ASO) probes for high-throughput clinical diagnoses. HUMAN NTN-2 nucleic acids are also used to modulate cellular expression or intracellular concentration or availability of active
- HUMAN NTN-2 inhibitory nucleic acids are typically antisense - single stranded sequences comprising complements of the disclosed natural HUMAN NTN-2 coding sequences.
- Antisense modulation of the expression of a given HUMAN NTN-2 polypeptide may employ antisense nucleic acids operably linked to gene regulatory sequences.
- Cells are transfected with a vector comprising a HUMAN NTN-2 sequence with a promoter sequence oriented such that transcription of the gene yields an antisense transcript capable of binding to endogenous HUMAN NTN-2 encoding mRNA.
- Transcription of the antisense nucleic acid may be constitutive or inducible and the vector may provide for stable extrachromosomal maintenance or integration.
- single- stranded antisense nucleic acids that bind to genomic DNA or mRNA encoding a given HUMAN NTN-2 polypeptide may be administered to the target cell, in or temporarily isolated from a host, at a concentration that results in a substantial reduction in expression of the targeted polypeptide.
- An enhancement in HUMAN NTN-2 expression is effected by introducing into the targeted cell type HUMAN NTN-2 nucleic acids which increase the functional expression of the corresponding gene products.
- nucleic acids may be HUMAN NTN-2 expression vectors, vectors which upregulate the functional expression of an endogenous allele, or replacement vectors for targeted correction of mutant alleles.
- Techniques for introducing the nucleic acids into viable cells are known in the art and include retroviral- based transfection, viral coat protein-liposome mediated transfection, etc.
- the invention provides efficient methods of identifying agents, compounds or lead compounds for agents active at the level of HUMAN NTN-2 modulatable cellular function.
- these screening methods involve assaying for compounds which modulate HUMAN NTN-2 interaction with a natural HUMAN NTN-2 binding target.
- assays for binding agents are provided including protein-protein binding assays, immunoassays, cell based assays, etc.
- Preferred methods are amenable to automated, cost-effective high throughput screening of chemical libraries for lead compounds.
- In vitro binding assays employ a mixture of components including a HUMAN NTN-2 polypeptide, which may be part of a fusion product with another peptide or polypeptide, e.g., a tag for detection or anchoring, etc.
- the assay mixtures comprise a natural HUMAN NTN-2 binding target. While native binding targets may be used, it is frequently preferred to use portions thereof as long as the portion provides binding affinity and avidity to the subject HUMAN NTN-2 conveniently measurable in the assay.
- the assay mixture also comprises a candidate pharmacological agent.
- Candidate agents encompass numerous chemical classes, though typically they are organic compounds, preferably small organic compounds, and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. A variety of other reagents such as salts, buffers, neutral proteins, e.g., albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc., may also be included.
- the mixture components can be added in any order that provides for the requisite bindings and incubations may be performed at any temperature which facilitates optimal binding.
- the mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the HUMAN NTN-2 specifically binds the cellular binding target, portion or analog with a reference binding affinity. Incubation periods are chosen for optimal binding but are also minimized to facilitate rapid, high throughput screening.
- the agent-biased binding between the HUMAN NTN-2 and one or more binding targets is detected by any convenient way.
- a separation step is often used to separate bound from unbound components. Separation may be effected by precipitation, immobilization, etc., followed by washing by, e.g., membrane filtration or gel chromatography.
- one of the components usually comprises or is coupled to a label.
- the label may provide for direct detection as radioactivity, luminescence, optical or electron density, etc., or indirect detection such as an epitope tag, an enzyme, etc.
- a variety of methods may be used to detect the label depending on the nature of the label and other assay components, e.g., through optical or electron density, radiative emissions, nonradiative energy transfers, or indirectly detected with antibody conjugates, etc.
- a difference in the binding affinity of the HUMAN NTN-2 polypeptide to the target in the absence of the agent as compared with the binding affinity in the presence of the agent indicates that the agent modulates the binding of the HUMAN NTN-2 polypeptide to the corresponding binding target.
- a difference is statistically significant and preferably represents at least a 50%, more preferably at least a 90% difference.
- the invention provides for a method for modifying the physiology of a cell comprising an extracellular surface in contact with a medium, said method comprising the step of contacting said medium with an exogenous HUMAN NTN-2 polypeptide under conditions whereby said polypeptide specifically interacts with at least one of a component of said medium and said extracellular surface to effect a change in the physiology of said cell.
- the invention further provides for a method for screening for biologically active agents, said method comprising the steps of a) incubating a HUMAN NTN-2 polypeptide in the presence of an extracellular HUMAN NTN-2 polypeptide specific binding target and a candidate agent, under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity; b) detecting the binding affinity of said polypeptide to said binding target to determine an agent- biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target.
- One embodiment of the invention is an isolated HUMAN NTN-2 polypeptide comprising the amino acid sequence as set forth herein or a fragment thereof having HUMAN NTN-2-specific activity.
- Another embodiment of the invention is a recombinant nucleic acid encoding HUMAN NTN-2 polypeptide comprising the amino acid sequence as set forth herein or a fragment thereof having HUMAN NTN-2- specific activity.
- the present invention also provides for antibodies to the HUMAN NTN-2 polypeptide described herein which are useful for detection of the polypeptide in, for example, diagnostic applications.
- antibodies to the HUMAN NTN-2 polypeptide described herein which are useful for detection of the polypeptide in, for example, diagnostic applications.
- any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
- the monoclonal antibodies for diagnostic or therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies.
- Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16).
- Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851, Takeda et al, 1985, Nature 314:452).
- HUMAN NTN-2 polypeptide described herein.
- various host animals can be immunized by injection with the HUMAN NTN-2 polypeptide, or a fragment or derivative thereof, including but not limited to rabbits, mice and rats.
- adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin) and Corvnebacterium parvum.
- BCG Bacille Calmette-Guerin
- a molecular clone of an antibody to a selected HUMAN NTN-2 polypeptide epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof. The present invention provides for antibody molecules as well as fragments of such antibody molecules. Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
- such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
- Antibody molecules may be purified by known techniques, e.g., immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC
- SEQ. I.D. NO. 1 Using the nucleotide sequence of SEQ. I.D. NO. 1 as a query, additional database searches were performed to identify overlapping ESTs. Two additional clones from the I.M.A.G.E. consortium were discerned to contain homologous sequence. These clones, GeneBank Accession Nos. AA166695 and T87299 were obtained from Research Genetics, Inc. (Huntsville, AL) and sequenced using the ABI 373A DNA sequencer and Taq Dideoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA). Alignment of the two additional clones with SEQ. I.D. NO. 1 indicated a total length of 680 nucleotides.
- Oligonucleotides were designed based on the partial human sequence and used as primers for the reverse transcriptase reaction and for PCR. A 608 nucleotide long sequence was obtained and used as a probe to isolate the full length sequence as described below.
- EXAMPLE 2 ISOLATION AND SEQUENCING OF FULL LENGTH cDNA CLONE ENCODING HUMAN NTN-2
- a human placenta cDNA library in lambda gt-10 was obtained from
- a fragment corresponding to nucleotides 216 to 824 of the hNTN-2 sequence shown in SEQ. I.D. NO. 3 was radiolabeled and utilized in Northern analysis of various human tissue specific RNAs.
- the Northern blot containing polyA+ RNA from several human tissues was obtained from Clontech Laboratories, Inc. (Palo Alto, CA) and was hybridized at 65°C to the radiolabeled hNTN-2 probe in the presence of 0.5M NaP04 (pH 7), 1% bovine serum albumin (Fraction V, Sigma), 7% SDS, 1 mM EDTA and 100 ng/ml sonicated, denatured salmon sperm DNA. The filter was washed at
- the hNTN-2 probe hybridized strongly to a 2.7 kb transcript in human heart, placenta, pancreas and lung tissue (Figure 1) and hybridized weakly to
- RNA from brain and liver could also be found in skeletal muscle and kidney.
- High expression of hNTN-2 in heart tissue may suggest that the present invention may be utilized to treat heart disease.
- Expression of hNTN-2 in lung and pancreas tissue may suggest that the present invention may be utilized to treat lung and /or pancreas related disorders.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4877697P | 1997-06-06 | 1997-06-06 | |
US48776P | 1997-06-06 | ||
US6638797P | 1997-11-21 | 1997-11-21 | |
US66387P | 1997-11-21 | ||
PCT/US1998/011294 WO1998055621A1 (en) | 1997-06-06 | 1998-06-03 | Ntn-2 member of tnf ligand family |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0991759A1 true EP0991759A1 (de) | 2000-04-12 |
Family
ID=26726521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98923907A Withdrawn EP0991759A1 (de) | 1997-06-06 | 1998-06-03 | Ntn-2, mitglied von tnf-ligand-familie |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0991759A1 (de) |
JP (1) | JP2002517977A (de) |
AU (1) | AU7608898A (de) |
CA (2) | CA2292835A1 (de) |
IL (1) | IL133316A0 (de) |
WO (1) | WO1998055621A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
WO1999011791A2 (en) * | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
CA2310987A1 (en) * | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Tnf ligand family gene |
US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
WO1999033980A2 (en) * | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000026244A2 (en) * | 1998-11-04 | 2000-05-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A novel tumor necrosis factor family member, drl, and related compositions and methods |
GB9828628D0 (en) * | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
EA007471B1 (ru) * | 1999-01-07 | 2006-10-27 | Займодженетикс, Инк. | Растворимый рецептор br43x2 и способы его применения |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
TR200102147T2 (tr) | 1999-01-25 | 2002-04-22 | Biogen, Inc. | BAFF, ilişkili bloke edici maddeler ve bunların bağışıklık karşılığında B-hücreleri ve imünoglobülinlerin uyarımı ve engellenmesinde kullanımları |
US6475986B1 (en) * | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
WO2000047740A2 (en) * | 1999-02-12 | 2000-08-17 | Amgen Inc. | Tnf-related proteins |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
PL207501B1 (pl) | 1999-08-17 | 2010-12-31 | Apotech R & D Sa | Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
EP1280826B1 (de) | 2000-05-12 | 2007-05-02 | Amgen Inc. | Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen |
KR101155294B1 (ko) | 2000-06-16 | 2013-03-07 | 캠브리지 안티바디 테크놀로지 리미티드 | 면역특이적으로 BLyS에 결합하는 항체 |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
AU2001288301A1 (en) | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
CN100448891C (zh) | 2001-05-11 | 2009-01-07 | 安姆根有限公司 | 与tall-1结合的肽和相关分子 |
DE60234202D1 (de) | 2001-05-24 | 2009-12-10 | Zymogenetics Inc | Taci-immunoglobulin-fusionsproteine |
EP1608730B1 (de) | 2003-03-28 | 2013-11-06 | Biogen Idec MA Inc. | Verkürzte baff-rezeptoren |
US20050255560A1 (en) * | 2003-11-21 | 2005-11-17 | Zeren Gao | Ztnf11, a tumor necrosis factor |
CA2583900A1 (en) * | 2004-10-13 | 2006-04-27 | The Washington University | Use of baff to treat sepsis |
KR20080056714A (ko) | 2005-08-09 | 2008-06-23 | 지모제넥틱스, 인코포레이티드 | TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법 |
EP1922079A2 (de) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Verfahren zur behandlung und prävention abnormaler zellproliferation mittels taci-fusionsmolekülen |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
JP6088723B2 (ja) | 2005-11-23 | 2017-03-01 | ジェネンテック, インコーポレイテッド | B細胞アッセイに関する組成物及び方法。 |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
BRPI0711823A2 (pt) | 2006-05-15 | 2012-01-17 | Ares Trading Sa | métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
CN106367714A (zh) | 2015-07-24 | 2017-02-01 | 先健科技(深圳)有限公司 | 铁基可吸收植入医疗器械与预制管及其制备方法 |
US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000052796A (ko) * | 1996-10-25 | 2000-08-25 | 벤슨 로버트 에이치. | 뉴트로킨 알파 |
WO1998027114A2 (en) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
-
1998
- 1998-06-03 CA CA002292835A patent/CA2292835A1/en not_active Abandoned
- 1998-06-03 JP JP50275099A patent/JP2002517977A/ja active Pending
- 1998-06-03 IL IL13331698A patent/IL133316A0/xx unknown
- 1998-06-03 AU AU76088/98A patent/AU7608898A/en not_active Abandoned
- 1998-06-03 EP EP98923907A patent/EP0991759A1/de not_active Withdrawn
- 1998-06-03 CA CA002292899A patent/CA2292899A1/en not_active Abandoned
- 1998-06-03 WO PCT/US1998/011294 patent/WO1998055621A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9855621A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2292835A1 (en) | 1998-12-10 |
CA2292899A1 (en) | 1998-12-10 |
JP2002517977A (ja) | 2002-06-18 |
AU7608898A (en) | 1998-12-21 |
IL133316A0 (en) | 2001-04-30 |
WO1998055621A1 (en) | 1998-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU743490B2 (en) | NTN-2 member of TNF ligand family | |
WO1998055621A1 (en) | Ntn-2 member of tnf ligand family | |
US6475987B1 (en) | Tall-1 receptor homologues | |
BG65519B1 (bg) | Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение | |
WO1999007738A2 (en) | Human orphan receptor ntr-1 | |
AU9230398A (en) | Cysteine rich receptors-train | |
JPH11225774A (ja) | 免疫グロブリン遺伝子スーパーファミリーのメンバー、pigr−1 | |
US20020160451A1 (en) | Novel orphan receptors | |
AU748167B2 (en) | Novel nucleic acid and polypeptide | |
WO1997042321A9 (en) | Osteoclast transporter protein | |
WO1997042321A1 (en) | Osteoclast transporter protein | |
AU2675197A (en) | Novel protein - traf6 | |
CA2339968A1 (en) | Dcr5, a bmp-binding protein, and applications thereof | |
WO2000018800A1 (en) | Novel secreted immunomodulatory proteins and uses thereof | |
WO1999026980A1 (en) | Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators | |
AU753400C (en) | Orphan receptors | |
US6207413B1 (en) | Nucleic acids encoding novel orphan cytokine receptors | |
JPH11215989A (ja) | 免疫グロブリン遺伝子スーパーファミリーのメンバー、pigr−2 | |
JP2002518061A (ja) | T110関連タンパク質ファミリーの新規な分子及びその使用 | |
JPH1072495A (ja) | 免疫関連因子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991207 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20011127 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020608 |